“From Drug Development to Production”: Global Big Pharma Expands Investment in China, Accelerating Its Rise as a Biotech and Pharmaceutical Powerhouse

U.S. pharmaceutical company Eli Lilly is expanding its investment in China's biotech market. Alongside committing substantial funds to expanding local manufacturing facilities and supply chains, it is stepping up joint drug development with local biotech companies and efforts to secure next-generation technologies. This push to increase investment in China extends beyond Eli Lilly to global Big Pharma more broadly, while the Chinese government is strengthening policy support to foster its pharmaceutical and biotech industries.